The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events

Thrombosis and Haemostasis

Volumn 83, Issue 4, 2000, Pages 563-570

  D'Angelo, Armando ^a,e   Coppola, Antonio ^d   Madonna, Pasquale ^d   Fermo, Isabella ^b   Pagano, Anna ^d   Mazzola, Giuseppina ^a   Galli, Laura ^c   Cerbone, Anna Maria ^d  

^a IRCCS H S Raffaele ^*  (Italy)

^b University of Naples Federico II ^*  (Italy)

^c Unit of Epidemiology   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Folate; Hyperhomocysteinemia; Juvenile thrombosis; Methionine synthase; Vitamin B12 5,10 methylenetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHIONINE SYNTHASE; METHYLENETETRAHYDROFOLIC ACID; 5 METHYLTETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE; 5 METHYLTETRAHYDROFOLIC ACID; 5-METHYLTETRAHYDROFOLATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASE; TETRAHYDROFOLIC ACID DERIVATIVE;

ADOLESCENT; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; FOLIC ACID BLOOD LEVEL; GENE MUTATION; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOSIS; VITAMIN BLOOD LEVEL; AMINO ACID SUBSTITUTION; BLOOD; CASE CONTROL STUDY; CYANOCOBALAMIN DEFICIENCY; DIET RESTRICTION; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETICS; ITALY; MIDDLE AGED; NUTRITIONAL REQUIREMENT; ONSET AGE; PHYSIOLOGY; POINT MUTATION; RISK FACTOR; SEX DIFFERENCE; THROMBOPHILIA;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ADOLESCENT; ADULT; AGE OF ONSET; AGED; AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; FASTING; FEMALE; FOLIC ACID; GENE FREQUENCY; GENETIC HETEROGENEITY; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; ITALY; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NUTRITIONAL REQUIREMENTS; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; RISK FACTORS; SEX FACTORS; TETRAHYDROFOLATES; THROMBOPHILIA; THROMBOSIS; VITAMIN B 12; VITAMIN B 12 DEFICIENCY;

EID: 0034168107     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613864     Document Type: Article

References (52)

1. Boushey CJ, Beresford SAA, Omenn GS. Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
2. Boers GHJ. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromh Haemost 1997; 78: 520-2.
3. D'Angelo A, Selhub J. Homocysteine and thrombolic disease. Blood 1997; 90: 1-11.
4. 12 concentrations and risk of early-onset coronary artery disease. Am J Clin Nutr 1994; 59:940-8.
5. Falcon CR. Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arterioscl Thromh 1994; 14: 1080-3.
6. Fermo I, Vigano' D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial thrombosis. Ann Intern Med 1995; 123: 747-53.
7. Refsum H. Ueland PM, Nygard O. Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Medicine 1998; 49: 31-62.
8. Kang SS, Wong PWK. Genetic and non-genetic factors for moderate hyperhomocysteinemia. Atherosclerosis 1994; 119: 135-8.
9. Skovby F. Inborn errors of metabolism causing homocysteinemia and related vascular involvement. Haemostasis 1989; 19 (Suppl. 1): 4-9.
10. Kang SS, Zhou J, Wong PWK. Kowalisyn J, Strokoseh G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-21.
11. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995; 10: 111-3.
12. Selhub J, D'Angelo A. Relationship between homocysteine and thrombotic disease. Am J Med Sci 1998; 316: 129-41.
13. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81: 165-76.
14. Kang SS., Wong PWK, Bock HO. Horowitz A, Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet 1991; 48: 546-51.
15. 6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 1992; 55: 1154-60.
16. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in the elderly. JAMA 1993; 270: 2693-8.
17. Lindenbaum J, Rosenberg IH, Wilson PWF, Stahler SP. Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994; 60: 2-11.
18. Rang SS, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987; 36: 458-62.
19. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindehaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988; 81:466-74.
20. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromh Vasc Biol 1995; 15: 1314-20.
21. Verhoef P, Kok FJ, Kruyssen DACM, Sehouten EG, Witteman CM, Grobhee DE, Ueland PM, Refsum H. Plasma total homocysteine, B vitamins and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:989-95.
22. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentration. Circulation 1996; 93: 7-9.
23. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Sehlub J, Horshford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-6.
24. Schwartz, SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, Psaty BM, Longstreth WT, Koepsell TD. Raghunathan TE, Reitsma PH. Myocardial infarction in young women in relation to plasma total homocysteine, folate and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96: 412-7.
25. Christensen B, Frosst P, Lussier-Cacan S. Selhuh J, Goyette P, Rosenblatt D. Genst J. Rozen R. Correlation of a common mutation in the methylenetetrahydrofolate reductase (MTHFR) gene with plasma homocysteine in patients with premature coronary artery disease. Arteriosel Thromb Vasc Biol 1997; 17: 569-73.
26. Verhoef P, Kok FJ, Kluijtmans LA, Blom HJ, Refsum H. Ueland PM, Kruyssen DA. The 677C >T mutation in the methylenetetrahydrol'olate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 1997; 13: 105-13.
27. Girelli D, Friso S, Trabelli E, Olivieri O, Russo C, Pessotto R, Faccini G, Pignatti PF, Mazzucco A, Corrocher R, Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from Northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998; 91: 4158-63.
28. Guttormsen AB, Ueland PM, Nesthus I, Nygard O, Schneede J. Vollsel SE. Refsum H. Determinants and vitamin responsiveness of intermediate HHcy (≥40 μmol/liter). J Clin Invest 1996; 98: 2174-83.
29. Leelere D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, Eydoux P, Rosenblatt DS, Rozen R, Gravel RA. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996; 5: 1867-74.
30. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988; 16: 1215.
31. de Franchis R, Mancini FP, D'Angelo A, Sebastio G, Fermo I, De Stefano V, Margaglione M, Mazzola G, Di Minno G. Andria G. Elevated total plasma homocysteine and 677C->T mutation of the 5,10 methylenetetrahydrololate reductase gene in thrombotic vascular disease. Am J Hum Genet 1996; 59: 262-4.
32. Fermo I, Arcelloni C, De Vecchi E, Viganò D'Angelo S, D'Angelo A, Paroni R. High-performance liquid chromatografic method with fluorescence detection for the determination of total homocyst(e)ine in plasma. J Chromatogr 1992; 593: 171-6.
33. Kluijtmans LAJ, den Heijer M. Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep vein thrombosis. Thromb Haemost 1998; 79: 254-8.
34. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
35. Kluijtmans LAJ, Kastelein JJP, Lindemans J, Boers GHJ, Heil SG, Bruschke AVG, Jukema JV, van den Heuvel LPWJ, Trijbels FJM, Boerma GJM, Verheugt FWA, Willems F, Blom HJ. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1997; 96: 2573-7.
36. Brattström L. Common mutation in the methylenetetrahydrofolate reducytase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. Circulation 1997; 96: 3805-6.
37. D'Angelo A. Beltrametti C. Venous disease. In "Homocysteine in Health and Disease" (R. Carmel and D. W. Jacobsen eds), Cambridge University Press. New York 1999; in press.
38. Evans RW, Shaten BJ, Hempel JD, Cutler JA. Kuller LH. for the MRFIT Research Group. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
39. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE. Prospective study of coronary heart disease incidence in relation to fasting homocysteinc, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998; 98: 204-10.
40. Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S, on behalf of the EARS group. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. Atherosclerosis 1998; 136: 347-54.
41. den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinemia a risk factor for recurrent thrombosis? Lancet 1995; 345: 882-5.
42. Deloughery TG, Evans A. Sadeghi A, McWilliams J, Henner D, Taylor LM Jr. Press RD. Common mutation in methylenetetrahydrofolate reductase: correlation with homocysteine metabolism and late-onset vascular disease. Circulation 1996; 94: 3074-8.
43. Brattström L. Vitamins as homocysteine lowering agents. J Nutr 1996; 126: 1276S-80S.
44. Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, Block PC, Holzgang CR, Anderson PH, Seltzer D. Upson B, Lin QR. The effects of folic acid supplementation on plasma homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscl Thromb Vasc Biol 1997; 17: 1157-62.
45. den Heijer M, Brower IA, Bos GM, Blom HJ, van der Put NM, Spaans AP, Rosendaal FR, Thomas CM, Haak HL, Wijermans PW. Gerrits WB. Vitamin supplementation reduces blood homocysteine levels. A controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998; 18: 356-61.
46. Verhoef P, Klujitmans LAJ, Blom HJ, Kok FJ. The A2756G mutation in the gene coding for methionine synthase: associations with plasma homocysteine and coronary atherosclerosis. Ned J Med 1998; 52: S52.
47. Morita H, Kurihara H, Sugiyama T, Hamada C. Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y. Polymorphism of the methionine synthase gene: association with homocysteine metabolism and late-onset vascular disease in the Japanese population. Arterioscl Thromb Vasc Biol 1999; 19: 298-302.
48. 12 metabolism associated with homocystinemia, cystathioninemia, hypomethioninemia and methylmalonic aciduria. Am J Med 1970; 48: 390-7.
49. Goodman SI. Moe PG, Hammond KB, Mudd SH, Uhlendorf BW. Homocystinuria with methylmalonic aciduria: two cases in a sibship. Biochem Med 1970; 4: 500-15.
50. 12 metabolism: effects on sulfur amino acid metabolism. Biochem Med 1970; 4: 193-214.
51. 6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary heart disease. Circulation 1998; 97: 437-43.
52. de Franchis R, Fermo I, Mazzola G, Sebastio G, Di Minno G, Coppola A, Galli L, Buoniconti A, Andria A, D'Angelo A. A common mutation of the cystathionine β-synthase gene (844INS68) is a risk factor for early-onset thrombosis and a determinant of fasting hyperhomocysteinemia only when associated to the thermolabile variant of methylenetetrahydrofolate reductase. Blood 1998; 92 (Suppl 1): 560a.